Technology
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Videos
    • Research
    • Patent Portfolio
    • Consumer Products
  • Licensing Opportunities
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Analyst Coverage
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Legend Removal
    • Governance
  • Education
    • Background
    • Resources
    • General FAQs
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 05, 2019 8:30am EDT

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

Aug 27, 2019 6:15am EDT

Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Aug 22, 2019 6:15am EDT

Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

Aug 15, 2019 6:15am EDT

Lexaria Bioscience Announces it has Received Four New Patents

Aug 14, 2019 6:15am EDT

Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

Aug 13, 2019 6:15am EDT

Lexaria Bioscience Receives Cannabis R&D License from Health Canada

Aug 08, 2019 6:15am EDT

Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

Aug 02, 2019 6:15am EDT

Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

Jul 30, 2019 6:15am EDT

Lexaria Bioscience Summarizes its Eleven Technology Licenses

Jul 24, 2019 6:10am EDT

Lexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership

  • Previous
  • 1…
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …17
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
medical cannabinoid research Lexaria Bioscience Corp. | Medical Cannabinoid Research | Home Logo

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

  • Home
  • About
  • Technology
  • Licensing Opportunities
  • Investors
  • News
  • Blog
  • Education
  • Events
  • Contact

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2022 All rights reserved. Web Design, Kelowna Photographers, SEO by Hiilite